Volume 2, Issue 3, August 2017, Page: 69-74
Analytical Method Development and Validation of Simultaneous Estimation of Paracetamol, Aceclofenac and Serratiopeptidase by RP-HPLC
Bhavani Podili, Department of Chemistry, Acharya Nagarjuna University, Guntur, India
Mohan Seelam, Department of Chemistry, Bapatla Engineering College, Bapatla, India
Prasada Rao Kammela, Department of Chemistry, Bapatla Engineering College, Bapatla, India
Received: Mar. 30, 2017;       Accepted: Apr. 24, 2017;       Published: Jun. 19, 2017
DOI: 10.11648/j.ijovs.20170203.12      View  1317      Downloads  88
Abstract
In this study, high performance chromatographic method have been developed and validated for the estimation of Paracetamol (PC), Aceclofenac (AF), and Serratio peptidase (SP) in combined tablet dosage form. The chromatography was carried out on a phenomenex C18 (Luna) coloumn (250mmX 4.6mm, 5µm) with a mobile phase consisting of buffer containing 1gm heptanesulfonic acid in 1lit water (adjusted to pH 2.5 with ortho phosphoric acid) acetonitrile (90:10 v/v) at a flow rate of 1.0 mL/min and ultraviolet detection at 226 nm. The retention time of PC, AF and SP were 3.119, 7.196 and 13.560 minutes respectively. Validation of the proposed method was carried out according to International Conference on Harmonisation (ICH) guidelines. Linearity range was obtained for PC, AF and SPover the concentration range of 2.1-31.5, 0.66-9.90 and 0.1-1.5 µg/mL and the r2 values were 0.9995, 0.9998 and 0.9992 respectively. The calculate limit of detection (LOD) values were 0.21, 0.066, and 0.01µg/mL and limit of quantitation (LOQ) values were 0.42, 0.132 and 0.02µg/mL for PC, AF, and SP correspondingly.
Keywords
Paracetamol (PC), Aceclofenac (AF), Serratio Peptidase (SP), RP-HPLC
To cite this article
Bhavani Podili, Mohan Seelam, Prasada Rao Kammela, Analytical Method Development and Validation of Simultaneous Estimation of Paracetamol, Aceclofenac and Serratiopeptidase by RP-HPLC, International Journal of Ophthalmology & Visual Science. Vol. 2, No. 3, 2017, pp. 69-74. doi: 10.11648/j.ijovs.20170203.12
Copyright
Copyright © 2017 Authors retain the copyright of this article.
This article is an open access article distributed under the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0/) which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
Reference
[1]
N. Y. Hasan, M. Abdel-Elkawy, B. E. Elzeany, N. E. Wagieh, Farmaco, 2003, 58, 91.
[2]
Y. S. El-Saharty, M. Refaat, S. Z. El-Khateeb, Drug. Develop. Ind. Pharm, 2002, 28, 571.
[3]
N. H. Zawilla, M. A. Mohammad, N. M. El-Kousy, S. M. El-MoghazyAly, J. P harm. Biomed. Anal, 2002, 27, 243.
[4]
B. Hinz, D. Auge, T. Rau, S. Reitbrock, K. Brune, U. Werner, Biomed. Chromatogr, 2003, 17, 268.
[5]
XQ. Liu, X. J. Chen, L. H. Zhao, J. H. Peng, Yao XueBao, 1997, 32, 546.
[6]
H. S. Lee, C. K. Jeong, S. J. Choi, S. B. Kim, M. H. Lee, G. I. Ko, D. H. Sohn, J. Pharm. Biomed. Anal, 2000, 23, 775.
[7]
N. M. El-Kousy, J. Pharm. Biomed. Anal, 1999, 20, 185.
[8]
L. S. Jensen, J. Valentine, R. W. Milne, A. M. Evans, J. Pharm. Biomed. Anal, 2004, 34, 585.
[9]
M. Ohta, N. Kawakami, S. Yamato, K. Shimada, J. Pharm. Biomed. Anal, 2003, 15, 1759.
[10]
P. Ortega-Barrales, R. Padilla-Weigand, A. Molina-Diaz, Anal. Sci, 2002, 18, 1241.
[11]
E. Dnic, C. Yucesoy, F. Onur, J. Pharm. Biomed. Anal, 2002, 15, 1091.
[12]
J. E. F. Reynolds,\Martindale The Extra Pharmacopoeia", 31st ed., pp. 27-28, Pharmaceutical Press, London, 1996.
[13]
The United States Pharmacopoeia, 24th revision, pp. 17-39, U. S. Pharmacopeial Convention, Rockville, MD, 2000.
[14]
The Indian pharmacopoeia commission “Indian Pharmacopoeia” (2010), Ghaziabad 1859, 2230.
[15]
Dissolution Profile of Aceclofenac Tablets Available in Bangladesh. S. J Pharm Sci. 2010, 3(1), 1-3.
[16]
R. Sivakumar, P. E. Venkataraman, R. Natarajan, V. Ganeasn, K. A. A. Ali, Comparative in vitro Evaluation of Commercial Aceclofenac Tablets. Int. J Chem Sci. 2009, 7(3), 1591-1594.
[17]
K. Raza, M. Kumar, P. Kumar, R. Malik, G. Sharma, M. Kauret al. Topical Delivery of Aceclofenac: Challenges and Promises of Novel Drug Delivery Systems. Biomed Res. Int. 2014, 2014: 1-11.
[18]
R. Yamazaki, S. Kawai, T. Matsuzaki, N. Kaneda, S. Hashimoto, T. Yokokuraet al. Aceclofenac blocks prostaglandin E2 production following its intracellular conversion into cyclooxygenase inhibitors. Eur. J Pharmacol. 1997, 329(2-3), 181-187.
[19]
Brogden RN, Wiseman LR. Aceclofenac: a review of itspharmacodynamic properties and therapeutic potential inthe treatment of rheumatic disorders and in painmanagement. Drugs. 1996, 52(1), 113-124.
[20]
K. Nakahama, K. Yoshimura, R. Marumoto, M. Kikuchi, IS. Lee, T. Hase, H. Matsubara, Clining and sequencing of Serratiaproteasegene, Nucleic Acids Res, 1986, 14(14 ) 5843-55.
[21]
M. Isono, M. Kazutaka, R. Kodama, K. Tomoda, K. Miyata. Serratiaprotease Part I. Purification and general properties of the enzyme, Agricultural and Biological Chemistry, 1970, 34(2), 310-318.
[22]
C. K. Kokate, A. P. Purohit, S. B. Gokhale, Pharmacognosy, 14th ed. NiraliPrakashan, Mumbai, 2008, 12. 11.
Browse journals by subject